ALUR (allurion.com) יחס יתרת חוב לטווח ארוך להון

Allurion Technologies (ALUR) is scaling the production of intragastric balloons by leveraging a digital platform for recurring payments. Patents and medical device certifications create significant barriers to entry for competitors. The long-term debt-to-equity ratio reflects borrowing dynamics, where the current status is 0.00. However, the asset remains exposed to risks stemming from debt leverage and regulatory delays in the US.

The ratio is calculated as the sum of liabilities with a maturity of more than one year divided by equity. This metric determines the extent to which long-term development depends on borrowed funds, where the balance between stability and investment growth is critically important. For Allurion Technologies (ALUR), a moderate debt load offsets the risks of cyclical demand in aesthetic medicine. An optimal level of leverage ensures expansion in the obesity treatment market without the threat of bankruptcy. The trend in the ratio of long-term loans to equity confirms the financial discipline of Allurion Technologies (ALUR) management.